Sanofi to cut insulin prices for uninsured from $99 to $35, matching the insulin cap coming through Congress

2022-06-29

As the House-passed bill to cap the monthly price of insulin at $35 nationwide makes its way for a Senate vote soon, Sanofi announced Wednesday morning that beginning next month it will cut the monthly price of its insulins for uninsured Americans to $35, down from $99 previously. The announcement from Sanofi, which allows the uninsured to buy one or multiple Sanofi insulins (Lantus, Insulin Glargine U-100, Toujeo, Admelog, and Apidra) at $35 for a 30-day supply effective July 1, follows House passage (232-193) of the monthly cap in March, with just 12 Republicans voting in favor of the measure. While both the Senate and the House bills effectively cut what many of those who rely on insulin to stay alive will pay at the pharmacy counter, it doesn’t hit the prices set by the pharma manufacturers, nor does it help those who are uninsured. Majority Leader Chuck Schumer (D-NY) similarly said in March that a vote was coming soon then. Insulin juggernaut Eli Lilly — one of the big three manufacturers along with Novo Nordisk and Sanofi — previously told Endpoints News exclusively that it supports the bill. A Sanofi spokesperson similarly said the company supported the bill but with some reservations, telling Endpoints via email: Sanofi, meanwhile, says that all commercially insured people are eligible for its co-pay assistance programs, regardless of income or insurance, “which limits out-of-pocket expenses for a majority of people between $0 and $10.” But the company also confirmed that some diabetics taking Sanofi’s insulins would see savings with the House bill. In 2021, about 68% of patients with commercial insurance paid $35 or less out of pocket per fill for Sanofi’s Lantus, a spokesperson added, as did about 72% of patients with Medicare Part D. But some insulin price advocates don’t think this latest Sanofi move really goes far enough. “It’s not even a band-aid on a bullet wound, because it’s a voluntary program that Sanofi can end at any time,” Laura Marston, an attorney with type 1 diabetes who advocates for lower insulin prices, told Endpoints, adding:

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构